Retatrutide vs Tirzepatide Head-to-head comparison of the triple vs dual agonist
Smaller Biotechs and Collaborators: Companies like Zealand Pharma, Glycadia, and others have GLP-1 analogs or co-agonists in early trials, often in partnership with larger pharma (e.g., Novo Nordisk collaboration with Zealand)
With semaglutide and tirzepatide removed from the shortage list in 2024-2025, and a formal April 30, 2026 FDA proposal to remove both from the 503B bulks list, the 503B pathway is under active regulatory pressure
Watch the Ozempic trap. Even a won off-label Ozempic appeal can be clawed back later, since it stays off-label
Injection site reactions Redness, itching, swelling, and minor bruising occur in approximately 1.4% of semaglutide users and 2.4% of tirzepatide users
Insulin translates unfavourable lifestyle into obesity